Trending Topic

3d medical x ray of knee pain with arthritis inflammation and tendon injury, copy space
9 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

The use of immune checkpoint inhibitors (ICIs) in treating cancer has greatly improved survival outcomes, particularly in patients with advanced disease for whom successful treatment options have previously been limited. For example, in patients with metastatic melanoma, the median survival time has improved from just 6 months to approximately 6 years with the use of […]

Xenofon Baraliakos, EULAR 2022: Bimekizumab in Patients with Active Non-Radiographic Axial Spondyloarthritis – BE MOBILE 1

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jun 24th 2022

BE MOBILE 1 (ClinicalTrials.gov Identifier: NCT03928704) is a a phase 3 study investigating bimekizumab in the treatment of active non-radiographic axial spondyloarthritis. touchIMMUNOLOGY were delighted to speak with Prof. Xenofon Baraliakos (Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Germany) around the aims of the BE MOBILE 1 study and the safety and efficacy findings.

The abstract ‘Bimekizumab in Patients with Active Non-Radiographic Axial Spondyloarthritis: 24-Week Efficacy & Safety from BE MOBILE 1, a Phase 3, Multicentre, Randomised, Placebo‑Controlled Study.’ (Abstract number: POS0939) was presented at the European Congress of Rheumatology 2022, 1-4 June, 2022.

Questions

  1. What are the unmet needs in the treatment of patients with non-radiographic axial spondyloarthritis? (0:19)
  2. What is the rationale for the use of bimekizumab in the treatment of active non-radiographic axial spondyloarthritis? (1:20)
  3. What are the aims, design and eligibility criteria for the BE MOBILE 1 study? (2:27)
  4. What have been the efficacy findings at week 24? (3:10)
  5. What safety concerns are associated with the use of bimekizumab and what are the safety findings to date? (4:05)

Disclosures: Xenofon Baraliakos discloses consulting for Abbvie, BMS, Eli-Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB; receiving payment or honoraria for lectures from: Abbvie, BMS, Eli-Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB; receiving grant/ research support from Abbvie, Novartis and MSD; serving on advisory boards for Abbvie, BMS, Eli-Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB; receiving honoraria from Abbvie, BMS, Eli-Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB; participating in speaker’s bureaus for Abbvie, BMS, Eli-Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.

Filmed in coverage of the EULAR meeting 2022.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup